[Meta-analysis of triptan treatment in migraine].
Nakashima
Kenji
K
Department of Neurology, Institute of Neurological Sciences, Faculty of Medicine, Tottori University, 86 Nishi-machi, Yonago-shi, Tottori 683-8503, Japan.
Takeshima
Takao
T
Kowa
Hisanori
H
D002227:Carbazoles / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D023303:Oxazolidinones / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011759:Pyrrolidines / Q000627:therapeutic use; D044346:Receptor, Serotonin, 5-HT1D; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014363:Tryptamines
D002227:Carbazoles; D007211:Indoles; D023303:Oxazolidinones; D010880:Piperidines; D011759:Pyrrolidines; D044346:Receptor, Serotonin, 5-HT1D; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; C409045:almotriptan; C115647:eletriptan; C089750:zolmitriptan; C093622:rizatriptan; D018170:Sumatriptan; C108128:frovatriptan; C106783:naratriptan